About WHO AML
Acute myeloid leukemia (AML) is a blood cancer that starts in the bone marrow but moves quickly into the blood, often spreading to other parts of the body.1
What is AML?
AML starts in the cells that are supposed to mature into different types of blood cells. In AML, the abnormal bone marrow cells do not become healthy white blood cells or may develop into too many abnormal red blood cells or platelets. AML can progress quickly and be fatal within a few months if not treated.1
The age-adjusted incidence rate of AML is 3.5 per 100,000, affecting slightly more men than women.The average age of a patient with AML is 67 years, and very few cases of AML are diagnosed in those younger than 40.2
A few risk factors are known for AML, including:1
- exposure to radiation or to chemicals such as benzene
- prior treatment with chemotherapy or radiation therapy
Additionally, patients with certain blood conditions, including MDS, have an increased risk for developing AML.1
Many people who develop AML, however, have none of the above risk factors.
In early stages of AML, patients may first present with symptoms such as:1
- Shortness of breath
- Easy bruising or bleeding
- Petechiae (flat, pinpoint spots under the skin caused by bleeding)
- Weakness or feeling tired
- Weight loss or loss of appetite
The treatment of AML is usually divided into two phases: induction and consolidation. The aim of the induction stage is to kill off leukemia cells in the blood and bone marrow and put the cancer into remission. Induction therapy usually involves a combination of chemotherapy drugs. For some patients, monoclonal antibody-based therapies may be used. The antibodies target a protein found on the leukemia cells, bringing cancer-killing drugs with them.1
After induction, the consolidation phase of therapy is meant to kill remaining abnormal cells that are not active but that might start growing and cause a relapse. Consolidation may be done with either more chemo or a stem cell transplant.1
- National Cancer Institute. General Information About Adult Acute Myeloid Leukemia. Available at:http://www.cancer.gov/cancertopics/pdq/treatment/adultAML. Last updated 9/21/11.
- National Cancer Institue. SEER Stat Fact Sheets: Acute Myeloid Leukemia. Available at: http://seer.cancer.gov/statfacts/html/amyl.html. Last updated 10/28/11.
a. MDS-specific Indication
VIDAZA® is indicated for the treatment of adult patients who are not eligible for haematopoietic stem cell transplantation with:
- intermediate-2 and high-risk myelodysplastic syndromes (MDS) according to the International Prognostic Scoring System (IPSS),
- chronic myelomonocytic leukaemia (CMML) with 10-29% marrow blasts without myeloproliferative disorder
b. AML-specific Indication:
Treatment of adult AML patients who are not eligible for haematopoietic stem cell transplantation with 20-30% blasts and multi-lineage dysplasia, according to the WHO classification. WHO classifies RAEB-T patients with blasts ≥20% to <30% as AML patients.
This is an international website for VIDAZA® and is intended for healthcare professionals outside the US. The information on this site is not country-specific and may contain information that is outside the approved indications in the country in which you are located.
The information on this website is based on the European Summary of Product Characteristics (SmPC). Please refer to your country-specific website, or contact a Celgene representative in your country for the latest information specific to your country.